Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model

Mostrar otras versiones (1)

The COVID-19 pandemic progresses unabated in many regions of the world. An effective antiviral against SARS-CoV-2 that could be administered orally for use following high-risk exposure would be of substantial benefit in controlling the COVID-19 pandemic. Herein, we show that MK-4482, an orally admin...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenke, Kyle, Hansen, Frederick, Schwarz, Benjamin, Feldmann, Friederike, Haddock, Elaine, Rosenke, Rebecca, Meade-White, Kimberly, Okumura, Atsushi, Leventhal, Shanna, Hawman, David W., Ricotta, Emily, Bosio, Catharine M., Saturday, Greg, Feldmann, Heinz, Jarvis, Michael A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553153/
https://www.ncbi.nlm.nih.gov/pubmed/33052329
http://dx.doi.org/10.21203/rs.3.rs-86289/v1
Descripción
Sumario:The COVID-19 pandemic progresses unabated in many regions of the world. An effective antiviral against SARS-CoV-2 that could be administered orally for use following high-risk exposure would be of substantial benefit in controlling the COVID-19 pandemic. Herein, we show that MK-4482, an orally administered nucleoside analog, inhibits SARS-CoV-2 replication in the Syrian hamster model. The inhibitory effect of MK-4482 on SARS-CoV-2 replication was observed in animals when the drug was administered either beginning 12 hours before or 12 hours following infection in a high-risk exposure model. These data support the potential utility of MK-4482 to control SARS-CoV-2 infection in humans following high-risk exposure as well as for treatment of COVID-19 patients.

Ejemplares similares